www.tonixpharma.com Open in urlscan Pro
162.241.142.33  Public Scan

Form analysis
0 forms found in the DOM

Text Content

Skip to content

 * About
   * Leadership
     * Executive Team
     * Board of Directors
     * Scientific Advisory Board
   * Facilities
 * Therapeutic Areas
   * Central Nervous System
     * Fibromyalgia
     * Posttraumatic Stress Disorder
     * Long COVID
     * Cocaine Intoxication
     * Migraine
     * Depression
   * Immunology
     * Organ Transplant Rejection
     * Gastro-Intestinal Cancers
   * Infectious Disease
     * COVID-19
     * Long COVID
     * Monkeypox
     * Smallpox
   * Rare Disease
     * Prader-Willi Syndrome
 * Pipeline
   * Central Nervous System
     * TNX-102 SL
     * TNX-601 ER
     * TNX-1300
     * TNX-1900
   * Immunology
     * TNX-1500
     * TNX-1700
   * Infectious Disease
     * TNX-102 SL
     * TNX-1850
     * TNX-801
   * Rare Disease
     * TNX-2900
   * Scientific Presentations
   * Expanded Access Policy
 * Clinical Trials
 * News & Events
   * Tonix in the News
   * Press Releases
   * Investor Presentations
   * IR Events
   * Op-eds
 * Investors
   * News & Events
   * Presentations
   * Multimedia
   * Financial Info
   * Stock Data
   * SEC Filings
   * Governance
 * Careers
 * Contact Us

TONIX IS ENROLLING PARTICIPANTS IN A PHASE 3 TRIAL FOR FIBROMYALGIA (RESILIENT
STUDY) AND A PHASE 2 TRIAL FOR LONG COVID (PREVAIL STUDY). PLEASE VISIT CLINICAL
TRIALS.

We are committed to improving population health






We are committed to improving population health







OUR MISSION, VISION AND STRATEGY

OUR MISSION IS TO IMPROVE POPULATION HEALTH BY INVENTING AND DEVELOPING
INNOVATIVE THERAPIES AND VACCINES, THROUGH BROAD IN-HOUSE CAPABILITIES AND
CREATIVE COLLABORATIONS, TO HELP ADDRESS IMPORTANT UNMET NEEDS.

OUR VISION IS TO BE A LEADER IN PROVIDING NOVEL DRUG THERAPIES AND VACCINES TO
IMPROVE POPULATION HEALTH AROUND THE WORLD. 

OUR STRATEGY IS TO USE OUR INTEGRATED DEVELOPMENT ENGINE TO ADVANCE INNOVATIVE
PROGRAMS ACROSS MULTIPLE THERAPEUTIC AREAS INTO THE CLINIC WHILE MAXIMIZING
ASSET POTENTIAL.

TO LEARN MORE ABOUT US, VIEW OUR VIDEO.




LATEST NEWS

September 6, 2022

Tonix Pharmaceuticals Announces Oral Presentations Involving TNX-1500
(Fc-Modified Anti-CD40L mAb) at the International Congress of The
Transplantation Society (TTS 2022)

August 22, 2022

Tonix Pharmaceuticals Initiates Enrollment in Phase 2 PREVAIL Study of TNX-102
SL for the Treatment of Long COVID

August 9, 2022

Tonix Pharmaceuticals to Present at the 2022 Virtual Q3 Investor Summit

August 8, 2022

Tonix Pharmaceuticals Reports Second Quarter 2022 Financial Results and
Operational Highlights




ABOUT TONIX PHARMACEUTICALS

Tonix has a robust pipeline of programs in development stages ranging from
preclinical to mid-Phase 3, across multiple therapeutic modalities, employing
varied routes of administration. Tonix’s pipeline is managed by a team of
passionate professionals that are adept at advancing innovative programs into
the clinic.

While many of Tonix’s product candidates are proprietary, in-house developments,
it also has collaborations with world-class academic and non-profit research
organizations as well as license agreements with other biotech companies.


LEARN MORE ABOUT US




THERAPEUTIC AREAS

CENTRAL NERVOUS SYSTEM

Tonix is dedicated to finding cures for difficult to treat, widely occurring,
chronic disorders of the central nervous system including pain, neurological,
psychiatric and addiction conditions.* Our goal is to heal sufferings of
millions through scientific advancements.

IMMUNOLOGY

We are advancing scientific programs that focus on therapeutics to prevent organ
transplant rejection, to manage autoimmune conditions, and to improve responses
to immunotherapy in certain cancers.*

INFECTIOUS DISEASE

Tonix’s infectious disease portfolio targets pathogenic infections, including
the ongoing COVID-19 pandemic. Tonix is attacking COVID-19 using vaccines,
antivirals and a Long COVID therapeutic.* Pandemic preparedness is necessary to
combat infections like SARS-CoV-2.

RARE DISEASE

Tonix is committed to improving patient care, including for those suffering from
rare diseases and for which no drug has been approved. Rare diseases are often
caused by genetic disorders and are characterized by complex symptoms. A rare
disease is a condition that affects fewer than 200,000 people in the US as
defined in the Orphan Drug Act of 1983.

CENTRAL NERVOUS SYSTEM

Tonix is dedicated to finding cures for difficult to treat, widely occurring,
chronic disorders of the central nervous system including pain, neurological,
psychiatric and addiction conditions.* Our goal is to heal sufferings of
millions through scientific advancements.

LEARN MORE

IMMUNOLOGY

We are advancing scientific programs that focus on therapeutics to prevent organ
transplant rejection, to manage autoimmune conditions, and to improve responses
to immunotherapy in certain cancers.*

LEARN MORE

INFECTIOUS DISEASE

Tonix’s infectious disease portfolio targets pathogenic infections, including
the ongoing COVID-19 pandemic. Tonix is attacking COVID-19 using vaccines,
antivirals and a Long COVID therapeutic.* Pandemic preparedness is necessary to
combat infections like SARS-CoV-2.

LEARN MORE

RARE DISEASE

Tonix is committed to improving patient care, including for those suffering from
rare diseases and for which no drug has been approved. Rare diseases are often
caused by genetic disorders and are characterized by complex symptoms. A rare
disease is a condition that affects fewer than 200,000 people in the US as
defined in the Orphan Drug Act of 1983.

LEARN MORE



PIPELINE HIGHLIGHTS

Using our integrated clinical development engine, we advance innovative programs
into the clinic while maximizing asset potential.

Preclinical

Phase I

Phase II

Phase III

TNX-102 SL   Fibromyalgia (FM)
Mid-Phase III — RESILIENT study enrolling

Mid-Phase III

TNX-1300   Cocaine Intoxication / Overdose
Mid-Phase II — Breakthrough Therapy Designation

Mid-Phase II

TNX-1850   COVID-19 Vaccine
Phase I start — targeting 2H 2023

Preclinical

TNX-1500   Organ Transplant Rejection / Autoimmune Disorders
Phase I start — targeting 1H 2023

Preclinical

VIEW OUR COMPLETE PIPELINE



MANAGEMENT TEAM

“Many frontiers remain in the fields of medical science and drug development. At
Tonix, we have carefully chosen pursuits in immunology, rare diseases,
infectious diseases, and central nervous system disorders. We are building
capabilities in synthetic biology, precision medicine, protein engineering, and
vaccine manufacturing to develop better and safer medicines. Our ultimate goals
are to improve and extend the lives of millions of people and, importantly, to
reward the dedication and commitment of our stakeholders.”
— Dr. Seth Lederman, M.D., President and CEO, Tonix Pharmaceuticals

MEET OUR TEAM


*ALL OF TONIX’S PRODUCT CANDIDATES ARE INVESTIGATIONAL NEW DRUGS OR BIOLOGICS
AND HAVE NOT BEEN APPROVED FOR ANY INDICATION.


Sign up for Email Alerts

 * Contact Us
 * Privacy Policy
 * Terms of Use
 * Site Map

© 2022 Tonix Pharmaceuticals Holding Corp.

Cookie Notification
We use 1st and 3rd party cookies to enhance your experience of our website, save
your preferences, and provide us with information on how you use our website.
For more information, please refer to our Privacy Policy. By accessing or using
our website, you consent to our use of cookies. You may opt out of the use of
cookies by adjusting your browser settings.

Accept